Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry

2020 ◽  
Vol 70 (2) ◽  
pp. 108-115 ◽  
Author(s):  
Kei Kohno ◽  
Ayako Sakakibara ◽  
Akari Iwakoshi ◽  
Masaki Hasegawa ◽  
Shiro Adachi ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Classic Hodgkin Lymphoma

scholarly journals Immune-Checkpoint Blockade Therapy in Lymphoma

2020 ◽  
Vol 21 (15) ◽  
pp. 5456 ◽  
Author(s):  
Ayumi Kuzume ◽  
SungGi Chi ◽  
Nobuhiko Yamauchi ◽  
Yosuke Minami
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Malignant Lymphoma ◽  
Hodgkin Lymphoma ◽  
Immune Checkpoint ◽  
Immune Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Host Immune System ◽  
Cell Death Protein

Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective.

scholarly journals Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

2017 ◽  
Vol 8 (5) ◽  
pp. 175-180 ◽  
Author(s):  
Nathan D. Gay ◽  
Craig Y. Okada ◽  
Andy I. Chen ◽  
Emma C. Scott
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Brentuximab Vedotin ◽  
Post Transplantation ◽  
Future Directions ◽  
Hematopoietic Stem ◽  
Programmed Cell Death 1 ◽  
Accelerated Approval ◽  
Immunoglobulin Gamma

Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.

The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma

2019 ◽  
Vol 60 (11) ◽  
pp. 2646-2657 ◽  
Author(s):  
Mengqi Sun ◽  
Wenjia Su ◽  
Jingrong Qian ◽  
Hongxue Meng ◽  
Hongfei Ji ◽  
...  
Keyword(s):  
Cell Death ◽  
T Cell ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Prognostic Value ◽  
Non Hodgkin Lymphoma

scholarly journals Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

Haematologica ◽  
2018 ◽  
Vol 104 (1) ◽  
pp. e21-e24 ◽  
Author(s):  
Stephanie Sasse ◽  
Katharina Reddemann ◽  
Arjan Diepstra ◽  
Ilske Oschlies ◽  
Antje Schnitter ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Classical Hodgkin Lymphoma ◽  
Cell Death Protein

Back to life with checkpoint inhibitors in Hodgkin lymphoma

2016 ◽  
Vol 24 (2) ◽  
pp. 139-142 ◽  
Author(s):  
Reyad Dada ◽  
Jamal Zekri
Keyword(s):  
Cell Death ◽  
Immune System ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
System Response ◽  
High Dose ◽  
Activated T Cells ◽  
Programmed Cell Death 1

Cancer can escape the immune system through different mechanisms. One of which is the expression of program death ligand-1 (PD-L1). This ligand binds to programmed cell death 1 receptor on activated T cells, subsequently leading to inhibition of the immune response. Nivolumab is a novel antibody that binds to programmed cell death 1 and prevents such immune tolerance. Several recently published clinical trials confirmed the clinical efficacy of single agent nivolumab in pretreated patients with different cancer types. Publications on nivolumab in Hodgkin lymphoma are very scarce. We report on a 30-year-old man with stage IVB Hodgkin lymphoma, who failed nine lines of treatments including high-dose chemotherapy and autologous stem cell transplantation and brentuximab vedotin. He reached a major response after four cycles of nivolumab and got married. The available literature is being reviewed. Pre-treated Hodgkin lymphoma is amenable to novel immunotherapy. Nivolumab induces clinically meaningful responses with excellent tolerance. The drug enriches our treatment options by reviving the immune system response against cancer. Further clinical studies are needed to determine the effectiveness on a large patients’ cohort.

Sign in / Sign up

Export Citation Format

Share Document